Perrigo Co. Presents at UBS Global Healthcare Conference, May-20-2013 03:00 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Bradley Joseph, Senior Manager IR & Corp Comms, Judy L. Brown, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

Perrigo Co. reported unaudited consolidated earnings results for the third quarter and nine months ended March 30, 2013. For the quarter, the company reported net sales of $919,825,000 against $778,017,000 a year ago. Operating income was $178,606,000 compared to $146,070,000 a year ago. Income before income taxes was $160,087,000 compared to $134,621,000 a year ago. Net income was $111,924,000 or $1.18 per diluted share compared to $115,727,000 or $1.23 per diluted share for the same period a year ago. On non-GAAP basis, the company reported operating income of $208,199,000 compared to $171,683,000 a year ago. Income before income taxes was $191,288,000 compared to $160,234,000 a year ago. Net income was $134,073,000 compared to $132,679,000 a year ago. Adjusted diluted earnings per share were $1.42 against $1.41 a year ago. For the nine months, the company reported net sales of $2,572,594,000 against $2,341,482,000 a year ago. Operating income was $499,036,000 compared to $408,290,000 a year ago. Income before income taxes was $446,287,000 compared to $367,649,000 a year ago. Net income was $323,459,000 or $3.42 per diluted share compared to $285,924,000 or $3.04 per diluted share for the same period a year ago. Net cash from operating activities was $380,112,000 compared to $311,620,000 a year ago. Additions to property and equipment were $63,480,000 compared to $85,715,000 a year ago. On non-GAAP basis, the company reported operating income of $580,111,000 compared to $504,744,000 a year ago. Income before income taxes was $532,019,000 compared to $464,103,000 a year ago. Net income was $381,624,000 compared to $348,430,000 a year ago. Adjusted diluted earnings per share were $4.04 against $3.71 a year ago. The company is confirming the guidance which was provided on February 11, 2013, the closing date of the Rosemont acquisition, and continues to expect fiscal 2013 reported earnings to be between $4.67 and $4.87 per diluted share as compared to $4.18 in fiscal 2012. Excluding the charges outlined in Table III at the end of this release, the company continues to expect fiscal 2013 adjusted earnings to be between $5.53 and $5.73 per diluted share as compared to $4.99 in fiscal 2012. This range implies a year-over-year growth rate in adjusted earnings of 11% to 15% over fiscal 2012's adjusted earnings from continuing operations per diluted share. CapEx spending is now expected to be in a range of between $110 million and $140 million for the full year. The company expects fiscal 2013 consolidated new product revenue to be approximately $130 million.

Perrigo Company announced that its Board of Directors declared a quarterly dividend of $0.09 per share, payable on June 18, 2013 to shareholders of record on May 31, 2013.